Drugs that contain Fluticasone Furoate; Vilanterol Trifenatate
1. List of Breo Ellipta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE44874 | GLAXO GRP LTD | Phenethanolamine derivatives for treatment of respiratory diseases |
Mar, 2023
(a month from now) | |
| US7439393 | GLAXO GRP LTD | Phenethanolamine derivatives for treatment of respiratory diseases |
May, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7776895 | GLAXO GRP LTD | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases |
Sep, 2022
(4 months ago) | |
| US8511304 | GLAXO GRP LTD | Medicament dispenser |
Jun, 2027
(4 years from now) | |
| US9333310 | GLAXO GRP LTD | Medicament dispenser |
Oct, 2027
(4 years from now) | |
| US8113199 | GLAXO GRP LTD | Counter for use with a medicament dispenser |
Oct, 2027
(4 years from now) | |
| US8161968 | GLAXO GRP LTD | Medicament dispenser |
Feb, 2028
(4 years from now) | |
| US11116721 | GLAXO GRP LTD | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol |
Feb, 2029
(6 years from now) | |
| US8534281 | GLAXO GRP LTD | Manifold for use in medicament dispenser |
Mar, 2030
(7 years from now) | |
| US8746242 | GLAXO GRP LTD | Medicament dispenser |
Oct, 2030
(7 years from now) | |
Market Authorisation Date: 10 May, 2013
Treatment: Indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older; Long-term, once daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in patients with a history of exacerbations; Indicated for long-term, once-daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in pts with a history of exacerbations; For the long-term, once-daily maintenance treatment of airflow obstruction in patients with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in patients with a history of exacerbations; Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including bronchitis and/or emphysema; Indicated for the once-daily treatment of asthma in patients 18 years and older
Dosage: POWDER;INHALATION
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic